Vitamin D deficiency is associated with a worse prognosis in metastatic melanoma
Metrics: PDF 476 views | HTML 279 views | ?
Dmitriy Timerman1, Melissa McEnery-Stonelake2, Cara J. Joyce3, Vinod E. Nambudiri4, F. Stephen Hodi5, Elizabeth B. Claus6, Nageatte Ibrahim5,7 Jennifer Y. Lin4,5
1Harvard-MIT Health Sciences and Technology (HST), Harvard Medical School, Boston, MA, USA
2Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, USA
3Department of Biostatistics, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA
4Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
5Melanoma Program, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
6Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
7Merck Research Laboratories, Clinical Oncology, North Wales, PA, USA
Jennifer Y. Lin, email: firstname.lastname@example.org
Keywords: vitamin D deficiency, melanoma, 25(OH)D3
Received: June 20, 2016 Accepted: December 05, 2016 Published: December 28, 2016
Vitamin D deficiency (≤20 ng/mL) is associated with an increased incidence and worse prognosis of various types of cancer including melanoma. A retrospective, single-center study of individuals diagnosed with melanoma from January 2007 through June 2013 who had a vitamin D (25(OH)D3) level measured within one year of diagnosis was performed to determine whether vitamin D deficiency and repletion are associated with melanoma outcome. A total of 409 individuals diagnosed with histopathology-confirmed melanoma who had an ever measured serum 25(OH)D3 level were identified. 252 individuals with a 25(OH)D3 level recorded within one year after diagnosis were included in the study and the individual and melanoma characteristics such as age, sex, Breslow thickness, ulceration, stage, mitotic rate, and LDH were obtained from the medical record. A worse melanoma prognosis was associated with vitamin D deficiency (P=0.012), higher stage (P<0.001), ulceration (P=0.001), and higher mitotic rate (P=0.001) (HR 1.93, 95% CI 1.15-3.22). In patients with stage IV metastatic melanoma, vitamin D deficiency was associated with significantly worse melanoma-specific mortality (adjusted HR 2.06, 95% CI 1.10-3.87). Patients with metastatic melanoma who were initially vitamin D deficient and subsequently had a decrease or ≤20 ng/mL increase in their 25(OH)D3 concentration had significantly worse outcomes (HR 4.68, 95% CI 1.05-20.88) compared to non-deficient patients who had a >20 ng/mL increase. Our results suggest that initial vitamin D deficiency and insufficient repletion is associated with a worse prognosis in patients with metastatic melanoma.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.